Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "ED"

9043 News Found

Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr
News | May 13, 2025

Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr

The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025


Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr
News | May 13, 2025

Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr

The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025


Wanbury's Tanuku facility granted GMP certificate by ANVISA
Drug Approval | May 13, 2025

Wanbury's Tanuku facility granted GMP certificate by ANVISA

The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)


Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
News | May 13, 2025

Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr

The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025


Morepen Board proposed dividend after 23 years
News | May 13, 2025

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25


Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr
News | May 12, 2025

Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr

The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025


Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
News | May 12, 2025

Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr

The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025


Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr
News | May 12, 2025

Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr

The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025


Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM
News | May 08, 2025

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM

The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets


AstraZeneca's enhertu improved pCR in early-stage breast cancer
News | May 07, 2025

AstraZeneca's enhertu improved pCR in early-stage breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care